GlassScriptPhysician profile
Sowmya Chandra Reddy
NPI 1811252786
$6,334.47
in general payments reported to CMS, 2019-2025
19 companies · $4,684 in 2025
The $4,684 reported for 2025 was more than what 87% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.54 · 2020: $23.45 · 2021: $119 · 2022: $230 · 2023: $796 · 2024: $427 · 2025: $4,684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,800 · Food and Beverage: $2,359 · Travel and Lodging: $748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,800.00 |
| Food and Beverage | $2,359.30 |
| Travel and Lodging | $747.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $3,728.50 | 2025 | |
| Amgen INC. | $528.89 | 2023-2025 | Evenity, Krystexxa, Tepezza |
| Medtronic, INC. | $488.20 | 2022-2025 | Minimed 780g |
| Dexcom, INC. | $283.99 | 2023-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $233.94 | 2021-2024 | |
| Sequel Med Tech, LLC | $168.09 | 2025 | Twiist |
| Abbvie INC. | $167.09 | 2023-2024 | Synthroid |
| Tandem Diabetes Care, INC. | $128.19 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Exelixis INC. | $125.44 | 2023 | Cabometyx |
| Insulet Corporation | $119.93 | 2025 | Omnipod |
| Lilly USA, LLC | $103.56 | 2022 | |
| Genzyme Corporation | $76.11 | 2025 | |
| Novo Nordisk INC | $46.43 | 2020-2025 | Rybelsus, Ozempic |
| Philips North America LLC | $38.12 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.96 | 2025 | Xifaxan |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $20.45 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $20.04 | 2025 | Airsupra |
| United Therapeutics Corporation | $17.42 | 2019 | |
| Abbott Laboratories | $16.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sowmya Chandra Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.